Ariad Pharmaceuticals v. Eli Lilly — Federal Circuit En Banc Reaffirms Written Description as Separate Patent Requirement

Background

Ariad Pharmaceuticals, along with the Massachusetts Institute of Technology, the Whitehead Institute for Biomedical Research, and Harvard College, held U.S. Patent No. 6,410,516. The patent covered discoveries relating to NF-κB — a protein complex that plays a central role in controlling gene expression, particularly in immune responses and inflammation. The claimed invention was extraordinarily broad: the patent’s key claims covered “the use of all substances that achieve the desired result” of reducing NF-κB activity in a cell, without specifying any particular substance or class of substances.

Eli Lilly manufactured two drugs, Evista (raloxifene) and Xigris (drotrecogin alfa), that Ariad contended reduced NF-κB activity. Lilly argued the patent was invalid, among other reasons, for failing to satisfy the written description requirement of 35 U.S.C. § 112. The district court had found the patent valid and infringed, but a Federal Circuit panel reversed. The court then granted en banc review to resolve the foundational question of whether § 112 even contains a written description requirement separate from enablement.

The Court’s Holding

The Federal Circuit en banc answered definitively: yes, § 112, paragraph 1 contains a written description requirement independent of the enablement requirement, and that requirement serves a distinct function. The text of § 112 — requiring that the specification “contain a written description of the invention” — is not merely a restatement of the enablement requirement. Written description asks whether the inventor actually possessed the claimed invention at the time of filing; enablement asks whether the specification teaches a person of ordinary skill how to make and use it.

Applying the standard, the court held that Ariad’s broad genus claims failed the written description requirement. The specification described the NF-κB discovery and identified the pathway but did not disclose any representative compounds, structures, or classes of materials that actually reduce NF-κB activity. In effect, Ariad claimed all solutions to a problem without describing a single one — a “wish-list” of future inventions rather than a description of a completed invention. The court vacated the infringement judgment and remanded for entry of judgment of invalidity.

Key Takeaways

• Section 112 of the Patent Act contains a written description requirement that is separate from and serves a different purpose than the enablement requirement.
• To satisfy written description, the specification must demonstrate that the inventor possessed the claimed invention — not just identified a problem and claimed all solutions to it.
• Broad genus claims covering an entire functional category of compounds or substances are vulnerable to written description challenges unless the specification describes representative structures or a correlation between structure and function.
• The ruling has the greatest impact on biotechnology and pharmaceutical patents, where inventors often understand a biological mechanism but have not yet identified specific therapeutic agents.

Why It Matters

Ariad resolved a long-running controversy about whether § 112 contained two separate requirements or just one. By firmly establishing written description as an independent doctrine, the court created a powerful tool for defendants challenging broad biological and chemical patents — particularly genus claims in the pharmaceutical and biotech industries.

The practical consequence is significant: a company cannot obtain a patent that effectively claims the entire solution space for a biological problem simply by being the first to identify the problem and the desired result. The specification must describe enough of the solution — specific molecules, classes of compounds, or at least representative examples — for the patent to stake out a valid claim. For biotech innovators, this means investing in the experimental work to identify actual substances before filing for broad genus claims.